U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H10N2O
Molecular Weight 174.1996
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDARAVONE

SMILES

CC1=NN(C(=O)C1)C2=CC=CC=C2

InChI

InChIKey=QELUYTUMUWHWMC-UHFFFAOYSA-N
InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3

HIDE SMILES / InChI
Molecular Formula C10H10N2O
Molecular Weight 174.1996
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Edaravone is a free radical scavenger developed for the treatment of amyotrophic lateral sclerosis.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Edaravone crossed BBB in rats.

Originator

Approval Year

2017
411
Targets

Targets

Primary TargetPharmacologyConditionPotency
CHEMBL1689064: Hydroxyl Radical
1
Target ID: CHEMBL1689064: Hydroxyl Radical
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
RADICUT

Approved Use

Improvement of neurological symptoms, disorder of activities of daily living, and functional disorder associated with acute ischaemic stroke; Inhibition on progression of functional disorder in patients with amyotrophic lateral sclerosis (ALS).

Launch Date

2010
Primary
Approved
8583
RADICUT

Approved Use

Improvement of neurological symptoms, disorder of activities of daily living, and functional disorder associated with acute ischaemic stroke; Inhibition on progression of functional disorder in patients with amyotrophic lateral sclerosis (ALS).

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.48 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22762844/
30 mg 2 times / day multiple, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1049.3 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28872908/
60 mg 1 times / day multiple, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2030.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, sublingual
dose: 30 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2354 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.24 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22762844/
30 mg 2 times / day multiple, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1373.5 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28872908/
60 mg 1 times / day multiple, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5576.72 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, sublingual
dose: 30 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5981.91 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.52 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22762844/
30 mg 2 times / day multiple, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.86 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28872908/
60 mg 1 times / day multiple, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.83 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, sublingual
dose: 30 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.04 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/30241688/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
EDARAVONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
unhealthy, 58.8 years (range: 29 - 75 years)
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Disc. AE: Respiratory disorder, Respiratory failure...
AEs leading to
discontinuation/dose reduction:
Respiratory disorder (0.5%)
Respiratory failure (1.1%)
Toxic skin eruption (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Respiratory disorder 0.5%
Disc. AE
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
unhealthy, 58.8 years (range: 29 - 75 years)
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Toxic skin eruption 0.5%
Disc. AE
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
unhealthy, 58.8 years (range: 29 - 75 years)
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Respiratory failure 1.1%
Disc. AE
60 mg 1 times / day multiple, intravenous
Recommended
Dose: 60 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
unhealthy, 58.8 years (range: 29 - 75 years)
Health Status: unhealthy
Age Group: 58.8 years (range: 29 - 75 years)
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252

inducer
1087
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2B6
926

CYP2C8
1057

CYP2C19
2057

UGT1A1
246

UGT2B7
197

P-gp
1741

BCRP
910

OATP1B1
1079

OATP1B3
961

OAT1
725

OAT3
747

OCT2
779
CYP1A2
832

CYP2B6
669
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP1A2
2333
 no
CYP2B6
1160
 no
CYP2B6
1160
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2D6
2546
 no
CYP3A4
2633
 no
CYP3A4
2633
 no
OAT1
730
 no
OATP1B1
1095
 no
OATP1B3
970
 no
OCT2
782
 no
P-gp
1932
 no
UGT1A1
303
 no
UGT2B7
210
 no
BCRP
985
 yes [IC50 121 uM]
OAT1
730
 yes [IC50 13.6 uM]
edaravone sulfate
1
OAT3
749
 yes [IC50 2.74 uM]
edaravone sulfate
1
OAT3
749
 yes [IC50 72.3 uM]
CYP2C9
2497
 yes [IC50 84.5 uM]
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31530
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31530
ChemicalBook
CB02130134
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02130134
ChemicalBook
CB1287462
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1287462
eMolecules
529123
https://www.emolecules.com/cgi-bin/more?vid=529123
MolPort
MolPort-000-182-197
https://www.molport.com/shop/molecule-link/MolPort-000-182-197
Selleck Chemicals
Edaravone
http://www.selleckchem.com/products/Edaravone.html
ZINC
ZINC000018203737
http://zinc15.docking.org/substances/ZINC000018203737
PubMed

PubMed

TitleDatePubMed
Ginsenoside Rd attenuates Aβ25-35-induced oxidative stress and apoptosis in primary cultured hippocampal neurons.
2015-09-05
Change in soluble epoxide hydrolase (sEH) during cisplatin-induced acute renal failure in mice.
2015-08
A novel pyrazolone-based derivative induces apoptosis in human esophageal cells via reactive oxygen species (ROS) generation and caspase-dependent mitochondria-mediated pathway.
2015-04-25
Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice.
2014-10
Edaravone inhibits hypoxia-induced trophoblast-soluble Fms-like tyrosine kinase 1 expression: a possible therapeutic approach to preeclampsia.
2014-07
[Effects of edaravone on the expression of GRP78, Caspase-12, and neuron apoptosis in juvenile rat hippocampus after status convulsive].
2011-01
Edaravone, a novel antidote against lung injury and pulmonary fibrosis induced by paraquat?
2011-01
Protective effect of edaravone against PrP106-126-induced PC12 cell death.
2010-09-01
Protective effects of the free radical scavenger edaravone on acute pancreatitis-associated lung injury.
2010-03-25
Edaravone improves the expression of nerve growth factor in human astrocytes subjected to hypoxia/reoxygenation.
2010-03
Protective effect of edaravone, a free-radical scavenger, on ischaemia-reperfusion injury in the rat testis.
2010-03
Acute urinary retention and subsequent catheterization cause lipid peroxidation and oxidative DNA damage in the bladder: preventive effect of edaravone, a free-radical scavenger.
2009-09
[Effects of edaravone on the expression of interleukin-1beta, nuclear factor-kappaB and neuron apoptosis in juvenile rat hippocampus after status convulsion].
2009-08
Reactive oxygen species modulate growth of cerebral aneurysms: a study using the free radical scavenger edaravone and p47phox(-/-) mice.
2009-07
[Effects of edaravone on IRE1 mRNA expression and neuronal apoptosis in the hippocampus of rats with status convulsivus].
2009-06
Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells.
2009-03
Expression of angiotensin II and its receptors in the normal and hypoxic amoeboid microglial cells and murine BV-2 cells.
2009-02-18
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
2009-02
Expression of syndecan-2 in the amoeboid microglial cells and its involvement in inflammation in the hypoxic developing brain.
2009-02
Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus.
2009-01
Protective effect of edaravone against tobramycin-induced ototoxicity.
2009-01
Edaravone inhibits the induction of iNOS gene expression at transcriptional and posttranscriptional steps in murine macrophages.
2008-12
Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway.
2008-09
Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism.
2008-07
The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice.
2008-03-31
Edaravone prevents iNOS expression by inhibiting its promoter transactivation and mRNA stability in cytokine-stimulated hepatocytes.
2008-03
Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance.
2007-12
Amelioration of hepatic ischemia/reperfusion injury in the remnant liver after partial hepatectomy in rats.
2007-12
Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia.
2007-12
Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats.
2007-10
A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient.
2007-06
[Ischemic stroke associated with LH-RH analogue (leuprorelin) administration in a young woman].
2007-05
Edaravone reduces ischemia-reperfusion injury mediators in rat liver.
2007-01
Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum.
2006-08-07
Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia-reperfusion injury of the liver by limiting free radical-mediated tissue damage.
2006-06
An antioxidant treatment potentially protects myocardial energy metabolism by regulating uncoupling protein 2 expression in a chronic beta-adrenergic stimulation rat model.
2006-05-15
A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia.
2006-04
Edaravone inhibits rheumatoid synovial cell proliferation and migration.
2006-02
Effect of a novel free radical scavenger, edaravone, on puromycin aminonucleoside induced nephrosis in rats.
2005-10
A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation.
2005-07-27
MCI-186 (edaravone), a free radical scavenger, attenuates hepatic warm ischemia-reperfusion injury in rats.
2005-07
The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy.
2005-05
Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase.
2005-03
Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat.
2005-02-01
Free radical scavenger (edaravone) prevents endotoxin-induced liver injury after partial hepatectomy in rats.
2005-01
Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney.
2004-05
Edaravone, a newly developed radical scavenger, protects against ischemia-reperfusion injury of the small intestine in rats.
2004-01
Edaravone, a novel free radical scavenger, prevents liver injury and mortality in rats administered endotoxin.
2003-10
Normalization by edaravone, a free radical scavenger, of irradiation-reduced endothelial nitric oxide synthase expression.
2003-08-22
A free radical scavenger, edaravone, attenuates steatosis and cell death via reducing inflammatory cytokine production in rat acute liver injury.
2003-08
Patents

Patents

04207317
1
JP2004307364A
1
JP2005029573A
1
JP2011062529A
1
JPH03215426A
1

Sample Use Guides

In Vivo Use Guide
30 mg of edaravone diluted with an appropriate volume of physiological saline, intravenously over 30 minutes twice a day in the morning and the evening (stroke); 60 mg of edaravone diluted with an appropriate volume of physiological saline, intravenously over 60 minutes once a day (amyotrophic lateral sclerosis).
Route of Administration: Intravenous
In Vitro Use Guide
1 uM or more of edaravone inhibited cultured vascular endothelial cell injury in vitro caused by 15-HPETE (hydroperoxyeicosatetraenoic acid).
Substance Class Chemical
Created
by admin
on Wed Apr 02 16:31:00 GMT 2025
Edited
by admin
on Wed Apr 02 16:31:00 GMT 2025
Record UNII
S798V6YJRP
Record Status FAILED
Record Version
  • Download
Name Type Language
EDARAVONE
HSDB   INN   JAN   MART.   USAN   WHO-DD  
USAN   INN  
Official Name English
PHENYL METHYL PYRAZOLONE
INCI  
INCI  
Preferred Name English
3H-PYRAZOL-3-ONE, 2,4-DIHYDRO-5-METHYL-2-PHENYL-
Systematic Name English
COLOREX PMP
Brand Name English
NORPHENAZONE [MI]
Common Name English
NSC-12
Code English
NSC-2629
Code English
C.I. DEVELOPER 1
Common Name English
NORPHENAZONE
MI  
Common Name English
DEVELOPER Z
Common Name English
RADICUT
Brand Name English
EDARAVONE [USAN]
Common Name English
EDARAVONE [HSDB]
Common Name English
MCI-186
Code English
1-PHENYL-3-METHYL-5-PYRAZOLONE
Systematic Name English
EDARAVONE [ORANGE BOOK]
Common Name English
RADICAVA
Brand Name English
NSC-26139
Code English
JAROCOL PMP
Brand Name English
3-Methyl-1-phenyl-2-pyrazolin-5-one
Systematic Name English
PHENAZONE IMPURITY A [EP IMPURITY]
Common Name English
Edaravone [WHO-DD]
Common Name English
ANTIPYRINE RELATED COMPOUND A [USP-RS]
Common Name English
EDARAVONE [MART.]
Common Name English
EDARAVONE [JAN]
Common Name English
PHENYLMETHYLPYRAZOLONE
Systematic Name English
ANTIPYRINE RELATED COMPOUND A [USP IMPURITY]
Common Name English
edaravone [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1509
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
FDA ORPHAN DRUG 847021
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
WHO-ATC N07XX14
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
FDA ORPHAN DRUG 478215
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
FDA ORPHAN DRUG 754420
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
EU-Orphan Drug EU/3/15/1510
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
FDA ORPHAN DRUG 465514
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
Code System Code Type Description
JAPANESE REVIEW
RADICUT
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY APPROVED JUNE 2015
DRUG BANK
DB12243
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
RXCUI
1921877
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
CHEBI
31530
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
NSC
2629
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
NSC
12
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
SMS_ID
100000088126
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
CAS
89-25-8
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
MESH
C005435
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
DAILYMED
S798V6YJRP
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
ChEMBL
CHEMBL290916
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
PUBCHEM
4021
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
NSC
26139
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
CAS
942-32-5
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
ALTERNATIVE
HSDB
4102
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
WIKIPEDIA
EDARAVONE
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-891-0
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
CAS
19735-89-8
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
ALTERNATIVE
INN
7362
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
DRUG CENTRAL
4156
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
EVMPD
SUB06453MIG
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
MERCK INDEX
m8072
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1040016
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
ECHA (EC/EINECS)
213-390-4
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
ALTERNATIVE
NCI_THESAURUS
C74323
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
EPA CompTox
DTXSID9021130
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
FDA UNII
S798V6YJRP
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
USAN
DE-18
Created by admin on Wed Apr 02 16:31:00 GMT 2025 , Edited by admin on Wed Apr 02 16:31:00 GMT 2025
PRIMARY
Related Record Type Details
OAT-3
TRANSPORTER -> SUBSTRATE
OAT-1
TRANSPORTER -> SUBSTRATE
WEAK
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A6
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
OAT-3
TRANSPORTER -> INHIBITOR
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A4
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A3
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B4
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B15
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INDUCER
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B17
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A9
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INHIBITOR
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A10
METABOLIC ENZYME -> SUBSTRATE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> INHIBITOR
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A7
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A8
METABOLIC ENZYME -> SUBSTRATE
IN-VITRO
Km
Related Record Type Details
Structure of EDARAVONE SULFATE
METABOLITE INACTIVE -> PARENT
Structure of ANTIPYRINE
PARENT -> METABOLITE
Structure of EDARAVONE GLUCURONIDE
METABOLITE INACTIVE -> PARENT
Related Record Type Details
Structure of ANTIPYRINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ANTIPYRINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of EDARAVONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966